CorMedix up 22% at $9.66 in pre-market after Q4 revenue pre-announcement

Shares of CorMedix (CRMD) are up 22% or $1.73 at $9.66 per share after the company guided Q4 revenue of about $31M vs. consensus of $20.0M. Joe Todisco, CorMedix CEO, also commented, “I’m proud to announce our preliminary Q4 results today, including surpassing our guidance of becoming breakeven by year-end 2024. CorMedix continues to execute well on our key objectives particularly around our outpatient launch, and I am pleased with the implementation efforts we have seen thus far from key customers in the outpatient segment. Today’s announcement of our agreement for inpatient expansion with Syneos Health reinforces our commitment to grow DefenCath across settings of care. I believe we begin 2025 in a strong position and look forward to updating investors as we continue to execute over the months ahead.”